125 related articles for article (PubMed ID: 38297883)
21. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
22. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
23. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
25. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
26. Suppression of hepatitis B viral gene expression by protein-tyrosine phosphatase PTPN3.
Hsu EC; Lin YC; Hung CS; Huang CJ; Lee MY; Yang SC; Ting LP
J Biomed Sci; 2007 Nov; 14(6):731-44. PubMed ID: 17588219
[TBL] [Abstract][Full Text] [Related]
27. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
Puntigam LK; Jeske SS; Götz M; Greiner J; Laban S; Theodoraki MN; Doescher J; Weissinger SE; Brunner C; Hoffmann TK; Schuler PJ
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707816
[TBL] [Abstract][Full Text] [Related]
29. PTPN3 Could Βe a Therapeutic Target of Pancreatic Cancer.
Onishi H; Iwamoto N; Sakanashi K; Koga S; Oyama Y; Yanai K; Nakamura K; Nagai S; Fujimura A; Nakayama K; Ozono K; Yamasaki A
Anticancer Res; 2022 Jun; 42(6):2869-2874. PubMed ID: 35641270
[TBL] [Abstract][Full Text] [Related]
30. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.
Shayan G; Srivastava R; Li J; Schmitt N; Kane LP; Ferris RL
Oncoimmunology; 2017; 6(1):e1261779. PubMed ID: 28197389
[TBL] [Abstract][Full Text] [Related]
31. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
32. Normal TCR signal transduction in mice that lack catalytically active PTPN3 protein tyrosine phosphatase.
Bauler TJ; Hughes ED; Arimura Y; Mustelin T; Saunders TL; King PD
J Immunol; 2007 Mar; 178(6):3680-7. PubMed ID: 17339465
[TBL] [Abstract][Full Text] [Related]
33. TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer.
Wang Z; Zhu M; Dong R; Cao D; Li Y; Chen Z; Cai J; Zuo X
J Nanobiotechnology; 2023 Nov; 21(1):440. PubMed ID: 37993847
[TBL] [Abstract][Full Text] [Related]
34. Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus.
Nakamura H; Konnai S; Okagawa T; Maekawa N; Sajiki Y; Watari K; Kamitani K; Saito M; Kato Y; Suzuki Y; Murata S; Ohashi K
J Virol; 2023 Jan; 97(1):e0143022. PubMed ID: 36598199
[TBL] [Abstract][Full Text] [Related]
35. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
Li J; Jie HB; Lei Y; Gildener-Leapman N; Trivedi S; Green T; Kane LP; Ferris RL
Cancer Res; 2015 Feb; 75(3):508-518. PubMed ID: 25480946
[TBL] [Abstract][Full Text] [Related]
36. IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.
Sieviläinen M; Saavalainen J; Adnan-Awad S; Salo T; Al-Samadi A
Front Immunol; 2022; 13():812822. PubMed ID: 35359980
[TBL] [Abstract][Full Text] [Related]
37. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
38. PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation.
Sun R; Chen T; Li M; Liu Z; Qiu B; Li Z; Xu Y; Pan C; Zhang Z
Biomed Pharmacother; 2020 Jan; 121():109583. PubMed ID: 31706106
[TBL] [Abstract][Full Text] [Related]
39. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
Balança CC; Salvioni A; Scarlata CM; Michelas M; Martinez-Gomez C; Gomez-Roca C; Sarradin V; Tosolini M; Valle C; Pont F; Ferron G; Gladieff L; Vergez S; Dupret-Bories A; Mery E; Rochaix P; Fournié JJ; Delord JP; Devaud C; Martinez A; Ayyoub M
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33332284
[TBL] [Abstract][Full Text] [Related]
40. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.
Sun WZ; Lin HW; Chen WY; Chien CL; Lai YL; Chen J; Chen YL; Cheng WF
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
